HomeCompareFARCX vs MRK

FARCX vs MRK: Dividend Comparison 2026

FARCX yields 5.62% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $1.8K in total portfolio value· pulled ahead in Year 6
10 years
FARCX
FARCX
● Live price
5.62%
Share price
$14.87
Annual div
$0.84
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$803.84
Full FARCX calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — FARCX vs MRK

📍 MRK pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFARCXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FARCX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FARCX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FARCX
Annual income on $10K today (after 15% tax)
$477.42/yr
After 10yr DRIP, annual income (after tax)
$683.26/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $124.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FARCX + MRK for your $10,000?

FARCX: 50%MRK: 50%
100% MRK50/50100% FARCX
Portfolio after 10yr
$29.9K
Annual income
$877.07/yr
Blended yield
2.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

FARCX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FARCX buys
0
MRK buys
0
No recent congressional trades found for FARCX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFARCXMRK
Forward yield5.62%3.25%
Annual dividend / share$0.84$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$29.0K$30.7K
Annual income after 10y$803.84$950.29
Total dividends collected$6.9K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FARCX vs MRK ($10,000, DRIP)

YearFARCX PortfolioFARCX Income/yrMRK PortfolioMRK Income/yrGap
1$11,262$561.67$11,192$351.54+$70.00FARCX
2$12,641$591.15$12,524$392.70+$117.00FARCX
3$14,146$620.15$14,015$438.65+$131.00FARCX
4$15,785$648.59$15,682$489.96+$103.00FARCX
5$17,566$676.38$17,547$547.23+$19.00FARCX
6← crossover$19,499$703.46$19,632$611.16$133.00MRK
7$21,594$729.79$21,963$682.53$369.00MRK
8$23,861$755.32$24,571$762.18$710.00MRK
9$26,311$780.01$27,486$851.08$1.2KMRK
10$28,957$803.84$30,745$950.29$1.8KMRK

FARCX vs MRK: Complete Analysis 2026

FARCXStock

The investment seeks to provide above average current income and long-term capital appreciation. The fund normally invests at least 80% of the sum of its net assets and the amount of any borrowings for investment purposes in income-producing common stocks of publicly traded companies engaged in the real estate industry. The advisor expects to emphasize investments in equity REITs, although it may invest in all three kinds of REITs. It may invest up to 15% of its total assets in non-dollar denominated equity securities of non-U.S. issuers. Up to 15% of the fund&#39;s total assets may be invested in equity securities of emerging market issuers.

Full FARCX Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this FARCX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FARCX vs SCHDFARCX vs JEPIFARCX vs OFARCX vs KOFARCX vs MAINFARCX vs JNJFARCX vs ABBVFARCX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.